JP7096770B2 - 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 - Google Patents

発現強化座位の使用に基づいた抗体を作製するための組成物および方法 Download PDF

Info

Publication number
JP7096770B2
JP7096770B2 JP2018552794A JP2018552794A JP7096770B2 JP 7096770 B2 JP7096770 B2 JP 7096770B2 JP 2018552794 A JP2018552794 A JP 2018552794A JP 2018552794 A JP2018552794 A JP 2018552794A JP 7096770 B2 JP7096770 B2 JP 7096770B2
Authority
JP
Japan
Prior art keywords
rrs
vector
nucleotide sequence
hcf
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515666A5 (https=
JP2019515666A (ja
Inventor
ロバート バブ，
ダリャ ブラコフ，
ガン チェン，
ジェイムズ ピー． ファンデル，
ユ ジャオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2019515666A publication Critical patent/JP2019515666A/ja
Publication of JP2019515666A5 publication Critical patent/JP2019515666A5/ja
Priority to JP2021114374A priority Critical patent/JP2021164479A/ja
Application granted granted Critical
Publication of JP7096770B2 publication Critical patent/JP7096770B2/ja
Priority to JP2023201924A priority patent/JP7781128B2/ja
Priority to JP2025170326A priority patent/JP2025188169A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2018552794A 2016-04-20 2017-04-20 発現強化座位の使用に基づいた抗体を作製するための組成物および方法 Active JP7096770B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021114374A JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2025170326A JP2025188169A (ja) 2016-04-20 2025-10-08 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
US62/325,400 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021114374A Division JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019515666A JP2019515666A (ja) 2019-06-13
JP2019515666A5 JP2019515666A5 (https=) 2020-05-28
JP7096770B2 true JP7096770B2 (ja) 2022-07-06

Family

ID=58701851

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018552794A Active JP7096770B2 (ja) 2016-04-20 2017-04-20 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2021114374A Pending JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A Active JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2025170326A Pending JP2025188169A (ja) 2016-04-20 2025-10-08 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021114374A Pending JP2021164479A (ja) 2016-04-20 2021-07-09 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2023201924A Active JP7781128B2 (ja) 2016-04-20 2023-11-29 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
JP2025170326A Pending JP2025188169A (ja) 2016-04-20 2025-10-08 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Country Status (15)

Country Link
US (2) US11512144B2 (https=)
EP (1) EP3445781A1 (https=)
JP (4) JP7096770B2 (https=)
KR (3) KR102547738B1 (https=)
CN (2) CN109195986B (https=)
AR (1) AR109451A1 (https=)
AU (2) AU2017253241B2 (https=)
BR (1) BR112018071283A2 (https=)
CA (1) CA3015389A1 (https=)
EA (1) EA201892010A1 (https=)
IL (2) IL314779A (https=)
MX (2) MX2018012868A (https=)
SG (2) SG11201807885PA (https=)
TW (2) TW202415767A (https=)
WO (1) WO2017184832A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021164479A (ja) * 2016-04-20 2021-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
JP7522100B2 (ja) 2019-04-02 2024-07-24 中外製薬株式会社 標的特異的な外来遺伝子の導入方法
AU2020308002A1 (en) * 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
CN118159660A (zh) 2021-10-18 2024-06-07 瑞泽恩制药公司 多核苷酸的受控转录
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
TW202342755A (zh) * 2021-12-22 2023-11-01 美商建南德克公司 多載體重組酶介導的匣式交換
JPWO2023238949A1 (https=) * 2022-06-10 2023-12-14
TW202528546A (zh) 2023-09-07 2025-07-16 美商再生元醫藥公司 經共價表面修飾之腺相關病毒的生產及純化
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2026050618A1 (en) 2024-08-29 2026-03-05 Regeneron Pharmaceuticals, Inc. Polynucleotide constructs and cell lines for recombinant aav production

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP2012528594A (ja) 2009-06-02 2012-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フコシル化欠損細胞
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
ES2439874T3 (es) 2002-05-29 2014-01-27 Regeneron Pharmaceuticals, Inc. Sistema de expresión en eucariotas inducible
WO2004046340A2 (en) 2002-11-14 2004-06-03 Genentech, Inc. Intron fusion construct and method of using for selecting high-expressing production cell lines
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP2115136A4 (en) 2006-12-21 2010-05-19 Glaxosmithkline Llc NOVEL PROCEDURE
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
CN102575264A (zh) 2009-09-18 2012-07-11 瑟莱克斯公司 增加的转基因表达和加工的产品和方法
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN104011080B (zh) 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 用于真核细胞的全长抗体展示系统及其用途
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112017008022A2 (pt) 2014-10-23 2018-02-20 Regeneron Pharmaceuticals, Inc. célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse.
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
SG11201807885PA (en) * 2016-04-20 2018-10-30 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539349A (ja) 2006-06-02 2009-11-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP2012528594A (ja) 2009-06-02 2012-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド フコシル化欠損細胞
JP2012531439A (ja) 2009-06-26 2012-12-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
JP2015519914A (ja) 2012-06-22 2015-07-16 ロンザ バイオロジクス ピーエルシー 部位特異的組込み
JP2016507525A (ja) 2013-02-01 2016-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． キメラ定常領域を含む抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnol. Prog. (2015) Vol.31, No.6, pp.1645-1656
Cytotechnology (2006) Vol.51, pp.171-182

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021164479A (ja) * 2016-04-20 2021-10-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 発現強化座位の使用に基づいた抗体を作製するための組成物および方法

Also Published As

Publication number Publication date
KR102906454B1 (ko) 2026-01-02
IL262266A (en) 2018-11-29
SG10202010155YA (en) 2020-11-27
CA3015389A1 (en) 2017-10-26
AU2024220124A1 (en) 2024-10-17
MX2025003852A (es) 2025-05-02
AR109451A1 (es) 2018-12-12
US11512144B2 (en) 2022-11-29
IL314779A (en) 2024-10-01
JP2021164479A (ja) 2021-10-14
JP2019515666A (ja) 2019-06-13
IL262266B2 (en) 2025-01-01
US20190233544A1 (en) 2019-08-01
US20230130799A1 (en) 2023-04-27
KR20230098361A (ko) 2023-07-03
JP2025188169A (ja) 2025-12-25
TW201803986A (zh) 2018-02-01
TWI827531B (zh) 2024-01-01
KR102547738B1 (ko) 2023-06-26
JP2024023449A (ja) 2024-02-21
AU2017253241A1 (en) 2018-09-20
CN109195986A (zh) 2019-01-11
CN109195986B (zh) 2023-01-03
TW202415767A (zh) 2024-04-16
SG11201807885PA (en) 2018-10-30
CN116515757A (zh) 2023-08-01
JP7781128B2 (ja) 2025-12-05
KR20180134893A (ko) 2018-12-19
MX2018012868A (es) 2019-03-11
KR20260011194A (ko) 2026-01-22
BR112018071283A2 (pt) 2019-02-12
EP3445781A1 (en) 2019-02-27
AU2017253241B2 (en) 2024-07-04
IL262266B1 (en) 2024-09-01
US12528883B2 (en) 2026-01-20
WO2017184832A1 (en) 2017-10-26
EA201892010A1 (ru) 2019-03-29

Similar Documents

Publication Publication Date Title
JP7546015B2 (ja) 発現強化座位の使用に基づく抗体を作製するための組成物および方法
JP7096770B2 (ja) 発現強化座位の使用に基づいた抗体を作製するための組成物および方法
EA052803B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA046654B1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA051643B1 (ru) Композиции и способы получения антител, основанные на применении локуса, обеспечивающего повышенную экспрессию

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200417

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220405

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220412

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220624

R150 Certificate of patent or registration of utility model

Ref document number: 7096770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250